The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
The treatment of insulin dependent diabetes mellitus. May be used for diabetics who require an insulin of prompt onset and short duration. It is a suitable preparation for admixture with longer acting insulins. It is particularly useful where intermittent, short term or emergency therapy is required, during initial stabilisation and in the treatment of labile diabetes.
Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy.
The ELIXA Phase IIIb study designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide), from Sanofi, in adults with...
scPharmaceuticals Inc. announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the FDA seeking approval of Furoscix (subcutaneous furosemide) for the treatment of congestion in patients with heart failure.
scPharmaceuticals Inc. announced that the FDA has accepted for review the company’s New Drug Application (NDA) resubmission for Furoscix.
The treatment of insulin dependent diabetes mellitus. May be used for diabetics requiring a depot insulin of medium duration. Where a more rapid, intense onset is desirable it may be mixed with Hypurin Neutral.